Compared with placebo, semaglutide 2.0 mg (risk ratio = 7.73 [95% CI 5.62, 10.63]) and tirzepatide 15 mg (risk ratio = 7.01 [95% CI 5.73, 8.57]) were the most efficacious in achieving an HbA 1c target of 48 mmol/mol (6.5%) (ESM Table 9)
Close monitoring of both milk supply and infant growth is essential, and documented informed consent about potential risks and benefits should be obtained before starting treatment
antimetabolites (used to treat tumours and blood disorders)
Tirzepatide is not recommended for pregnant or breastfeeding individuals
Laboratory models by the team of Sikiric et al
A goal of an HbA1c less than 7% is incorporated in diabetes guidelines to reduce the risk of microvascular and macrovascular diabetes complications 2,3,4,5 , with 70% or more time spent in the target glucose range (3.910.0 mmol l 1 ), which is considered the goal threshold according to the CGM guidelines as it is associated with an HbA1c of 7% or less 6